Bullish & Foolish
Full QNCX fundamentals All 466 on the Survival Watch

QNCXQuince Therapeutics, Inc.

Is Quince Therapeutics struggling financially?

Yes, by its own account. Quince Therapeutics told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$34.5M
Source filing
10-Q 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

28+ mo

Runs out some time after Oct 2028, raising nothing.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$116.0M

÷

Cash burned over the last 12 months

$41.8M

What Quince Therapeutics told the SEC

…amount of cash and cash equivalent resources as of the issuance of these unaudited condensed consolidated financial statements, management concluded that substantial doubt exists with respect to the Company's ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have…

Quince Therapeutics, Inc., Form 10-Q, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 34% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt